CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenues
Finance receivable interest income, including fees	$ 39,310	$ 30,800
Pharmaceutical development	16,122	5,903
Other	723	9
Total revenues	56,155	36,712
Costs and expenses:
Impairment expense		163
Pharmaceutical manufacturing, research and development expense	7,347	4,268
General and administrative	13,620	10,546
Depreciation and amortization expense	4,061	12,091
Change in fair value of acquisition-related contingent consideration	(287)	4,400
Interest expense	374	455
Total costs and expenses	25,115	31,923
Other income (expense), net
Unrealized net gain (loss) on warrants	272	(586)
Unrealized net gain (loss) on equity securities	1,839	(591)
Realized (loss) gain on sale of investments	(140)	53
Income before income tax expense (benefit)	33,011	3,665
Income tax expense (benefit)	7,082	(1,537)
Consolidated net income	$ 25,929	$ 5,202
Net income per share
Basic	$ 2.03	$ 0.40
Diluted	$ 2.02	$ 0.40
Weighted Average Shares
Basic	12,796,000	12,852,000
Diluted	12,834,000	12,862,000